secwatch / observer

8-K filed April 27, 2026, 7:59 PM ET ticker ONCY CIK 0001129928

regulatory confidence high sentiment positive materiality 0.85

Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep

ONCOLYTICS BIOTECH INC

FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.
Prior pelareorep+checkpoint data showed median duration of response 15.5 months vs 9.5 months SOC; 12-month survival 82% vs 45.7%.
No FDA-approved therapies exist for SCAC after first-line chemo/checkpoint; over 10,000 US patients affected annually.
Company will finalize protocol using FDA feedback; study enables multiple endpoint assessments for potential simultaneous approvals.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001129928-26-000026
form_type: 8-K
ticker: ONCY
cik: 0001129928
company_name: ONCOLYTICS BIOTECH INC
filed_at: 2026-04-27T23:59:59+00:00
discovered_at: 2026-05-14T18:02:31.988667+00:00
generated_at: 2026-05-15T03:43:03.596952+00:00
sec_items: ["8.01", "9.01"]
event_type: regulatory
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001129928-26-000026
json_url: https://secwatch.observer/filing/0001129928-26-000026.json
markdown_url: https://secwatch.observer/filing/0001129928-26-000026.md
text_url: https://secwatch.observer/filing/0001129928-26-000026.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000026/0001129928-26-000026-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000026/oncy-20260427.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CING

Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only

Cingulate Inc. June 2, 2026, 8:10 AM ET regulatory Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days

Outlook Therapeutics, Inc. June 1, 2026, 9:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing

RICHTECH ROBOTICS INC. May 28, 2026, 4:49 PM ET regulatory Items 3.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

BBIO

FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026

BridgeBio Pharma, Inc. May 27, 2026, 4:01 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

OTLK

FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026

Outlook Therapeutics, Inc. May 26, 2026, 7:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

LRHC

La Rosa Holdings receives Nasdaq deficiency notice for late 10-K and 10-Q filings

La Rosa Holdings Corp. May 22, 2026, 5:20 PM ET regulatory Items 3.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

RGTI

Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity

Rigetti Computing, Inc. May 21, 2026, 7:30 AM ET regulatory Items 3.02, 8.01, 7.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

NNE

NRC accepts Nano Nuclear's construction permit application for KRONOS MMR at Univ. of Illinois

Nano Nuclear Energy Inc. May 20, 2026, 5:10 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001129928-26-000026

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.